IL-20R Activation via rIL-19 Enhances Hematoma Resolution through the IL-20R1/ERK/Nrf2 Pathway in an Experimental GMH Rat Pup Model

Oxid Med Cell Longev. 2021 Jan 19:2021:5913424. doi: 10.1155/2021/5913424. eCollection 2021.

Abstract

Aims: Blood clots play the primary role in neurological deficits after germinal matrix hemorrhage (GMH). Previous studies have shown a beneficial effect in blood clot clearance after hemorrhagic stroke. The purpose of this study is to investigate interleukin-19's role in hematoma clearance after GMH and its underlying mechanism of IL-20R1/ERK/Nrf2 signaling pathway.

Methods: A total of 240 Sprague-Dawley P7 rat pups were used. GMH was induced by intraparenchymal injection of bacterial collagenase. rIL-19 was administered intranasally 1 hour post-GMH. IL-20R1 CRISPR was administered intracerebroventricularly, or Nrf2 antagonist ML385 was administered intraperitoneally 48 hours and 1 hour before GMH induction, respectively. Neurobehavior, Western blot, immunohistochemistry, histology, and hemoglobin assay were used to evaluate treatment regiments in the short- and long-term.

Results: Endogenous IL-19, IL-20R1, IL-20R2, and scavenger receptor CD163 were increased after GMH. rIL-19 treatment improved neurological deficits, reduced hematoma volume and hemoglobin content, reduced ventriculomegaly, and attenuated cortical thickness loss. Additionally, treatment increased ERK, Nrf2, and CD163 expression, whereas IL-20R1 CRISPR-knockdown plasmid and ML385 inhibited the effects of rIL-19 on CD163 expression.

Conclusion: rIL-19 treatment improved hematoma clearance and attenuated neurological deficits induced by GMH, which was mediated through the upregulation of the IL-20R1/ERK/Nrf2 pathways. rIL-19 treatment may provide a promising therapeutic strategy for the GMH patient population.

MeSH terms

  • Animals
  • Animals, Newborn
  • Cerebral Hemorrhage / congenital
  • Cerebral Hemorrhage / drug therapy*
  • Cerebral Hemorrhage / metabolism
  • Cerebral Hemorrhage / pathology
  • Disease Models, Animal
  • Female
  • Hematoma / congenital
  • Hematoma / drug therapy
  • Hematoma / metabolism
  • Hematoma / pathology
  • Interleukins / pharmacology
  • Interleukins / therapeutic use*
  • MAP Kinase Signaling System / drug effects
  • MAP Kinase Signaling System / physiology
  • Male
  • NF-E2-Related Factor 2 / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Interleukin / agonists*
  • Receptors, Interleukin / metabolism
  • Recombinant Proteins / pharmacology
  • Remission Induction

Substances

  • Il19 protein, rat
  • Interleukins
  • NF-E2-Related Factor 2
  • Receptors, Interleukin
  • Recombinant Proteins
  • interleukin-20 receptor